

1 Timothy R. West
CA Bar #342526
2 **DV INJURY LAW WEST, PC / UTB LAW GROUP**
404 Camino Del Rio S, Suite 606
3 San Diego, CA 92108
T: (619) 202-0004
4 F: (619) 825-2661
timw@dvinjurylaw.com

5
6 *Attorneys for Plaintiff*

7
8 **IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF CALIFORNIA**

9
10 IN RE: ANGIODYNAMICS, INC., AND
11 NAVILYST MEDICAL, INC., PORT
CATHETER PRODUCTS LIABILITY
12 LITIGATION

13 SADARAH RHONE,

14 *Plaintiff,*

15 vs.

16 ANGIODYNAMICS, INC., AND
17 NAVILYST MEDICAL, INC.,

18 *Defendants.*

19 Civil Action No.:

Case No. 3:24-md-03125-JO-VET
MDL No. 3125

HON. JINSOOK OHTA

**COMPLAINT AND JURY
DEMAND**

20
21
22
23
24
25
26
27
28

1 Plaintiff files this Complaint pursuant to Case Management Order (CMO) No. 1
2 (“Direct Filing Order”), and is bound by the rights, protections, privileges, and obligations
3 of that CMO. In accordance with CMO No. 1, Plaintiff hereby designates the Western
4 District of Washington as Plaintiff’s designated venue (“Original Venue”) as this case may
5 have originally been filed in this District pursuant to 28 U.S.C. § 1391.

6 COMES NOW the Plaintiff, Sadarah Rhone, by and through Plaintiff’s
7 undersigned counsel, and brings this Complaint against AngioDynamics, Inc, and
8 Navilyst Medical, Inc. (collectively, the “Defendants”), and alleges as follows:

9 1. This is an action for damages arising out of the failure relating to
10 Defendants’ design, development, testing, assembling, manufacturing, packaging,
11 promoting, marketing, distribution, supplying, and/or selling the defective implantable
12 vascular access device sold under the trade name of Vortex (hereinafter “Vortex”, or
13 “Defective Device”).

14 **PARTIES**

15 2. Plaintiff, Sadarah Rhone, is a citizen and resident of Tacoma, Washington.

16 3. Defendant AngioDynamics, Inc. (“AngioDynamics”) is a Delaware
17 corporation with its principal place of business located in Latham, New York.
18 AngioDynamics is engaged in the business of researching, developing, designing,
19 licensing, manufacturing, distributing, supplying, selling, marketing, and introducing into
20 interstate commerce, either directly or indirectly through third parties or related entities,
21 its medical devices, including the Vortex.

22 4. Defendant Navilyst Medical, Inc. (“Navilyst”) is a Delaware corporation
23 with its principal place of business located in Marlborough, Massachusetts. Navilyst
24 conducts business throughout the United States, including the States of Washington and
25 California, and is a wholly owned subsidiary of AngioDynamics. Navilyst is engaged in

1 the business of researching, developing, designing, licensing, manufacturing,
2 distributing, supplying, selling, marketing, and introducing into interstate commerce,
3 either directly or indirectly through third parties or related entities, its medical devices,
4 including the Vortex.

5 **JURISDICTION AND VENUE**

6 5. This Court has subject matter jurisdiction over the parties pursuant to 28
7 U.S.C. §1332(a) because the parties are citizens of different states and the amount in
8 controversy exceeds \$75,000.00, exclusive of interest and cost.

9 6. Venue is proper in this Court pursuant to 28 U.S.C. §1391 by virtue of the
10 facts that (a) a substantial part of the events or omissions giving rise to the claims occurred
11 in the Original Venue and (b) Defendants’ products are produced, sold to and consumed
12 by individuals in the States of Washington and California, thereby subjecting Defendants
13 to personal jurisdiction in this action and making them all “residents” of this judicial
14 District.

15 7. Defendants have and continue to conduct substantial business in the State of
16 California and in the Original Venue, distribute vascular access products in the Original
17 Venue, receive substantial compensation and profits from sales of vascular access
18 products in the Original Venue, and made material omissions and misrepresentations and
19 breaches of warranties in the Original Venue, subjecting them to *in personam* jurisdiction
20 in the Original Venue.

21 8. Consistent with the Due Process Clause of the Fifth and Fourteenth
22 Amendments, this Court has in personam jurisdiction over Defendants, because
23 Defendants are present in the States of Washington and California, such that requiring an
24 appearance does not offend traditional notions of fair and substantial justice.

PRODUCT BACKGROUND

1
2 9. In or about 2003, a company called Horizon Medical Products (“Horizon”)
3 obtained clearance from the Triumph VTX Port with LiveValve Catheter under the
4 510(k) number K032557.

5 10. Shortly after the clearance of the Triumph port, Horizon merged with Rita
6 Medical Systems, which was in the process of being acquired by AngioDynamics.

7 11. The Vortex port system bears a design and specifications that differ
8 significantly from the Triumph port (including but not limited to the catheter design and
9 connection hub), but Defendants represented to regulatory authorities that the Vortex port
10 was cleared under the K032557 submission.

11 12. Neither Horizon Medical Products nor AngioDynamics received clearance
12 from the FDA to market the Vortex TR catheter, making such device per se misbranded
13 pursuant to the Food, Drug, and Cosmetic Act.

14 13. Defendant’s Vascular Access Devices were designed, patented,
15 manufactured, labeled, marketed, sold, and distributed by Defendants at all relevant times
16 herein.

17 14. The Vortex is one of several varieties of port/catheter systems that has been
18 designed, manufactured, marketed, and sold by Defendants.

19 15. According to Defendants, the Vortex is totally implantable vascular access
20 device designed to provide repeated access to the vascular system for the delivery of
21 medication, intravenous fluids, parenteral nutrition solutions, and blood products.

22 16. The intended purpose of the Vortex is to make it easier to deliver
23 medications directly into the patient’s blood stream. The device is surgically placed
24 completely under the skin and left implanted.

1 17. The Vortex is a system consisting of two primary components: an injection
2 port and a polyurethane catheter which includes additives intended to make it radiopaque.

3 18. The injection port has a raised center, or “septum,” where the needle is
4 inserted for delivery of the medication. The medication is carried from the port into the
5 bloodstream through a small, flexible tube, called a catheter, that is inserted into a blood
6 vessel.

7 19. The Vortex is indicated for patient therapies requiring repeated access to the
8 vascular system. The port system can be used for infusion of medications, I.V. fluids,
9 parenteral nutrition solutions, blood products, and for the withdrawal of blood samples.

10 20. The product’s catheter is comprised of a polymeric mixture of polyurethane
11 and a barium sulfate radiopacity agent.

12 21. Barium sulfate is known to contribute to reduction of the mechanical
13 integrity of polyurethane *in vivo* as the particles of barium sulfate dissociate from the
14 surface of the catheter over time, leaving microfractures and other alterations of the
15 polymeric structure and degrading the mechanical properties of the polyurethane.

16 22. Researchers have shown that catheter surface degradation in products
17 featuring a radiopaque barium sulfate stripe is concentrated at the locus of the stripe.¹

18 23. The mechanical integrity of barium sulfate-impregnated polyurethane is
19 affected by the concentration of barium sulfate as well as the heterogeneity of the
20 modified polymer.

21
22
23
24 ¹ See Hecker JF, Scandrett LA. Roughness and thrombogenicity of the outer surfaces of
25 intravascular catheters. *J Biomed Mater Res.* 1985;19(4):381-395.
26 doi:10.1002/jbm.820190404

1 24. Upon information and belief, Defendants' manufacturing process in
2 designing and constructing the catheter implanted in Plaintiff involved too high a
3 concentration of barium sulfate particles for the polymer formulation, leading to
4 improperly high viscosity of the admixed polyurethane before polymerization and
5 causing improper mixing of barium sulfate particles within the polymer matrix.

6 25. This defect in the manufacturing process led to a heterogeneous modified
7 polymer which led to an irregular catheter surface replete with fissure, pits and cracks.

8 26. Although the surface degradation and resultant mechanical failure can be
9 reduced or avoided with design modifications (*e.g.*, using a higher grade radiopacity
10 compound and/or encapsulating the admixed polymer within polyurethane), Defendants
11 elected not to incorporate those design elements into the Vortex.

12 27. At all times relevant, Defendants misrepresented the safety of the Vortex
13 system, and negligently designed, manufactured, prepared, compounded, assembled,
14 processed, labeled, marketed, distributed, and sold the Vortex system as safe and effective
15 device to be surgically implanted to provide repeated access to the vascular system for
16 the delivery of medications, intravenous fluids, parenteral nutrition solutions, and blood
17 products.

18 28. At all times relevant to this action, Defendants knew and had reason to know,
19 that the Vortex was not safe for the patients for whom they were prescribed and
20 implanted, because once implanted the device was prone to infection, thrombosis,
21 fracturing, migrating, perforating internal vasculature and otherwise malfunctioning.

22 29. At all times relevant to this action, Defendants knew and had reason to know
23 that patients implanted with a Vortex port had an increased risk of suffering life
24 threatening injuries, including but not limited to: death; hemorrhage; cardiac/pericardial
25 tamponade (pressure caused by a collection of blood in the area around the heart);

1 infection; cardiac arrhythmia and other symptoms similar to myocardial infarction;
2 severe and persistent pain; and perforations of tissue, vessels and organs, or the need for
3 additional surgeries to remove the defective device.

4 30. Soon after the Vortex was introduced to market, which was years before
5 Plaintiff was implanted with his device, Defendants began receiving large numbers of
6 adverse event reports (“AERs”) from health care providers reporting that the Vortex was
7 fracturing post-implantation and that fractured pieces were migrating throughout the
8 human body, including to the heart and lungs. Defendants also received large numbers of
9 AERs reporting that the Vortex was found to have perforated internal vasculature. These
10 failures were often associated with reports of severe patient injuries such as:

- 11 a. hemorrhage;
- 12 b. infection/ sepsis;
- 13 c. cardiac/pericardial tamponade;
- 14 d. cardiac arrhythmia and other symptoms similar to myocardial infarction;
- 15 e. severe and persistent pain;
- 16 f. perforations of tissue, vessels, and organs; and
- 17 g. upon information and belief, even death.

18 31. In addition to the large number of AERs which were known to Defendants
19 and reflected in publicly accessible databases, there are many recorded device failures
20 and/or injuries related to the Defendants’ implantable port products which were
21 concealed from medical professionals and patients through submission to the FDA’s
22 controversial Alternative Summary Reporting (“ASR”) program.

1 32. The FDA halted the ASR program after its existence was exposed by a multi-
2 part investigative piece, prompting a widespread outcry from medical professionals and
3 patient advocacy groups.²

4 33. Prior to the discontinuation of the ASR program, Defendants reported
5 numerous episodes of failures of their implanted port/catheter products – including
6 numerous episodes of thrombosis and blood clots – under the ASR exemption, thereby
7 concealing them from physicians and patients.

8 34. Defendants were aware or should have been aware that the Vortex had a
9 substantially higher failure rate than other similar products on the market, yet Defendants
10 failed to warn consumers of this fact.

11 35. Defendants also intentionally concealed the severity of complications
12 caused by the Vortex and the likelihood of these events occurring.

13 36. Rather than alter the design of the Vortex to make it safer or adequately warn
14 physicians of the dangers associated with the Vortex, Defendants continued to actively
15 and aggressively market the Vortex as safe, despite their knowledge of numerous reports
16 of infection, fracture, thrombosis, and associated injuries.

17 37. Moreover, Defendants concealed—and continue to conceal—their
18 knowledge of the Vortex’s dangerous propensity to precipitate thrombosis and blood
19 clots. Defendants further concealed their knowledge that the catheter design caused these
20 failures and that these failures cause serious injuries.

21
22
23
24 ² Christina Jewett, *Hidden Harm: Hidden FDA Reports Detail Harm Caused by Scores of*
25 *Medical Devices*, Kaiser Health News (Mar. 2019).

1 38. The conduct of Defendants, as alleged in this Complaint, constitutes willful,
2 wanton, gross, and outrageous corporate conduct that demonstrates a conscious disregard
3 for the safety of Plaintiff. Defendants had actual knowledge of the dangers presented by
4 the Vortex, yet consciously failed to act reasonably to:

- 5 a. Adequately inform or warn Plaintiff, his prescribing physicians, or the
6 public at large of these dangers;
- 7 b. Establish and maintain an adequate quality and post-market surveillance
8 system; or
- 9 c. Recall the Vortex System from the market.

10 **SPECIFIC FACTUAL ALLEGATIONS AS TO PLAINTIFF**

11 39. On or about January 5, 2017, Plaintiff underwent placement of an
12 AngioDynamics VortVTX catheter product, model number MP-P5PT, lot number
13 5073592. The Port Catheter was implanted by Dr. Lynn Clark, MD., at St. Joseph Medical
14 Center in Tacoma Washington.

15 40. Defendants, directly or through their agents, apparent agents, servants, or
16 employees designed, manufactured, marketed, advertised, distributed, and sold the
17 Vortex that was implanted in Plaintiff.

18 41. Defendants manufactured, sold, and/or distributed the Vortex to Plaintiff,
19 through Plaintiff's doctors, to be used for vein access.

20 42. In or about February 11, 2017, Plaintiff presented to the St. Joseph Medical
21 Center, with concerns related to her port site. Her medical team determined that she had
22 developed an infection as well as blood clots in the right internal jugular. The defective
23 port was subsequently removed.

1 43. Defendants, directly or through their agents, apparent agents, servants, or
2 employees designed, manufactured, marketed, advertised, distributed, and sold the
3 Vortex that was implanted in Plaintiff.

4 44. At all times, the Vortex was utilized and implanted in a manner foreseeable
5 to Defendants, as Defendants generated the instructions for use and created procedures
6 for implanting the product.

7 45. The Vortex implanted into Plaintiff was in the same or substantially similar
8 condition as when it left the possession of Defendants, and in the condition directed by
9 and expected by Defendants.

10 46. Plaintiff and Plaintiff's physicians foreseeably used and implanted the
11 Vortex, and did not misuse, or alter the Vortex in an unforeseeable manner.

12 47. Defendants advertised, promoted, marketed, sold, and distributed the Vortex
13 as a safe medical device when Defendants knew or should have known the Vortex was
14 not safe for its intended purposes and that the product could cause serious medical
15 problems.

16 48. Defendants had sole access to material facts concerning the defective nature
17 of the products and their propensity to cause serious and dangerous side effects.

18 49. In reliance on Defendants' representations, Plaintiff's doctor was induced
19 to, and did use the Vortex.

20 50. As a result of having the Vortex implanted, Plaintiff sustained significant
21 mental and physical pain and suffering, suffered permanent injury, permanent and
22 substantial physical deformity, underwent corrective surgery or surgeries, and suffered
23 financial or economic loss, including, but not limited to, obligations for medical services
24 and expenses.

1 51. Defendants' Vortex was marketed to the medical community and to patients
2 as safe, effective, reliable, medical devices; implanted by safe and effective, minimally
3 invasive surgical techniques for the treatment of medical conditions, and as safer and
4 more effective as compared to the traditional products and procedures for treatment, and
5 other competing Vascular Access Devices.

6 52. The Defendants have marketed and sold the Vortex to the medical
7 community at large and patients through carefully planned, multifaceted marketing
8 campaigns and strategies. These campaigns and strategies include, but are not limited to,
9 direct to consumer advertising, aggressive marketing to health care providers at medical
10 conferences, hospitals, private offices, and/or group purchasing organizations, and
11 include a provision of valuable consideration and benefits to the aforementioned.

12 53. The injuries, conditions, and complications suffered due to Defendants'
13 Vortex include but are not limited to hemorrhage; cardiac/pericardial tamponade; cardiac
14 arrhythmia and other symptoms similar to myocardial infarction; severe and persistent
15 pain; perforations of tissue, vessels and organs; and even death.

16 54. Defendants were negligent toward Plaintiff in the following respects:

- 17 a. Defendant failed to design and establish a safe, effective procedure for
18 removal of the Vortex; therefore, in the event of a failure, injury, or
19 complications, it is difficult to safely remove the Vortex.
- 20 b. Defendants provided incomplete, insufficient, and misleading information
21 to physicians in order to increase the number of physicians using the Vortex
22 for the purpose of increasing their sales. By so doing, Defendants caused
23 the dissemination of inadequate and misleading information to patients,
24 including the Plaintiff.

1 55. The Vortex was utilized and implanted in a manner foreseeable to
2 Defendants.

3 56. The Vortex implanted into Plaintiff was in the same or substantially similar
4 condition as when it left the possession of the Defendants, and in the condition directed
5 by the Defendants.

6 57. At the time of his operation, Plaintiff was not informed of, and had no
7 knowledge of the complaints, known complications, and risks associated with Vortex.

8 58. Plaintiff was never informed by Defendants of the defective and dangerous
9 nature of the Vortex.

10 59. At the time of Plaintiff's implant, neither Plaintiff nor Plaintiff's physicians
11 were aware of the defective and dangerous condition of the Vortex.

12 60. At the time of the injuries referenced herein, Plaintiff did not know that the
13 corrective surgery Plaintiff underwent was due to a defect in the Vortex.

14 61. As a direct and proximate result of the defective Vortex and the wrongful
15 acts and omissions of the Defendants as alleged herein, Plaintiff was injured due to the
16 use of the Vortex, which caused Plaintiff various physical, mental, and emotional injuries
17 and damages.

18 **DISCOVERY RULE AND TOLLING**

19 62. Plaintiff incorporates the preceding paragraphs as if set out fully herein.

20 63. Plaintiff's action has been filed within the applicable statute of limitations
21 period allowable pursuant to Washington law.³

22
23
24
25 ³ See RCW 4.16.080 (2), (4).

1 64. “Under the discovery rule, ‘a cause of action accrues when a claimant
2 knows, or in the exercise of due diligence should have known, all the essential elements
3 of the cause of action, specifically duty, breach, causation and damages.”⁴

4 65. Plaintiff’s doctor nor anyone else provided her information that informed
5 her of the causal link between Defendants’ port catheter device and her infection and
6 thrombosis. Throughout her treatment, the claimant reported ongoing issues with the port,
7 including discomfort, difficulty accessing the device during chemotherapy, and visible
8 abnormalities such as a lump near the port site. Despite these complaints, her concerns
9 were not taken seriously, and she was not advised of any potential defect or associated
10 risks. Without knowledge of a possible defect, she reasonably relied on her medical
11 providers and continued using the device as directed. This lack of awareness significantly
12 increased her risk of harm. Had the claimant been informed of a potential issue with the
13 port, she could have sought further evaluation, requested removal or replacement of the
14 device sooner or pursued alternative treatment options. Instead, she remained exposed to
15 a potentially defective device, which prolonged her exposure to complications and
16 increased the likelihood of developing serious conditions such as thrombosis. The delay
17 in identifying the cause of her symptoms prevented timely intervention and allowed her
18 condition to worsen, resulting in additional physical injury as well as ongoing mental and
19 emotional distress. It was not until 2025, when Plaintiff learned of the potential causal
20 link between Plaintiff’s port-related infection and thrombosis and the defective nature of
21 Defendant’s Vortex product by seeing an advertisement about defective port catheters
22 and sought legal counsel promptly after learning of the connectoin. Plaintiff’s case has
23

24
25 ⁴ *Funkhouser v. Wilson*, 950 P.2d 501, 512 (Wash. Ct. App. 1998) (quoting *In re Estates*
26 *of Hibbard*, 118 Wash.2d 737, 744, 826 P.2d 690 (1992)).

1 been filed within Washington’s statute of limitations period pursuant to the discovery
2 rule.

3 **FRAUDULENT CONCEALMENT**

4 66. The expiration of Washington’s three-year statute of limitations has been
5 equitably tolled by reason of Defendants’ fraudulent concealment, and fraudulent
6 conduct. Through affirmative misrepresentations and omissions, Defendants actively
7 concealed from Plaintiff the true risks associated with the implantation and use of
8 Defendants’ Vortex product.

9 67. Defendants actively concealed the defects, suppressed reports, failed and/or
10 continue to fail, to follow through on regulatory requirements, and failed and/or continue
11 to fail to disclose known defects to physicians. Instead of revealing the defects,
12 Defendants continued to represent that the Vortex is safe for its intended use.

13 68. Defendants are and were under a continuing duty to disclose the true
14 character, quality, and nature of risks and dangers associated with the Vortex. Due to
15 Defendants’ concealment of the true character, quality, and nature of the Vortex,
16 Defendants are estopped from relying on any statute of limitations defense.

17 69. Defendants furthered this fraudulent concealment through a continued and
18 systematic failure to disclose information to Plaintiff, Plaintiff’s healthcare Providers,
19 and the public.

20 70. Defendants’ acts before, during and/or after the act causing Plaintiff’s injury
21 prevented Plaintiff from discovering the injury or the cause of the injury.

22 71. Defendants’ conduct, as described in this Complaint, amounts to conduct
23 purposely committed, which Defendants must have realized was dangerous, heedless,
24 reckless, and without regard to the consequences or Plaintiff’s rights and safety.

1 72. Defendants' conduct, as described in this Complaint, also amounts to a
2 continuing tort, and continues up through and including the date of the filing of Plaintiff's
3 Complaint.

4 73. As a result of Defendants' actions, Plaintiff could not reasonably have
5 known or learned through reasonable diligence that she had been exposed to the risks
6 alleged herein associated with Defendants' Vortex product, and that those risks were the
7 direct and proximate result of Defendants' acts and omissions.

8 **FIRST CAUSE OF ACTION**
9 **NEGLIGENCE**

10 74. Plaintiff incorporates by reference the preceding paragraphs of this
11 Complaint as if fully set forth herein.

12 75. The Defendants owed Plaintiff a duty to exercise reasonable care when
13 designing, manufacturing, marketing, advertising, distributing, selling, and conducting
14 post-market surveillance of the Vortex.

15 76. The Defendants failed to exercise due care under the circumstances and
16 therefore breached this duty by:

- 17 a. Failing to properly and thoroughly test the Vortex before releasing the
18 device to market, and/or failing to implement feasible safety improvements;
- 19 b. Failing to properly and thoroughly analyze the data resulting from any pre-
20 market testing of the Vortex;
- 21 c. Failing to conduct sufficient post-market testing and surveillance of the
22 Vortex;
- 23 d. Designing, manufacturing, marketing, advertising, distributing, and selling
24 the Vortex to consumers, including Plaintiff, without an adequate warning
25 of the significant and dangerous risks of the Vortex and without proper

1 instructions to avoid the harm which could foreseeably occur as a result of
2 using the Vortex;

3 e. Failing to exercise due care when advertising and promoting the Vortex; and

4 f. Negligently continuing to manufacture, market, advertise, and distribute the
5 Vortex after Defendants knew or should have known of its adverse effects.

6 77. In performing the foregoing acts, omissions, and misrepresentations,
7 Defendants acted grossly negligent, fraudulently, and with malice so as to justify an
8 award of punitive and/or exemplary damages.

9 78. As a direct and proximate result of the aforementioned, Plaintiff was injured
10 due to the use of the Vortex, which caused Plaintiff various physical, mental, and
11 emotional injuries and damages. Accordingly, Plaintiff seeks compensatory damages.

12 **SECOND CAUSE OF ACTION**
13 **STRICT PRODUCTS LIABILITY – FAILURE TO WARN**

14 79. Plaintiff incorporates by reference the preceding paragraphs of this
15 Complaint as if fully set forth herein.

16 80. Defendants designed, set specifications, manufactured, prepared,
17 compounded, assembled, processed, marketed, labeled, distributed, and sold the Vortex,
18 including the one implanted into Plaintiff, into the stream of commerce and in the course
19 of same, directly advertised and marketed the device to consumers or persons responsible
20 for consumers, and therefore had a duty to warn of the risk of harm associated with the
21 use of the device and to provide adequate instructions on the safe and proper use of the
22 device.

23 81. At the time Defendants designed, manufactured, prepared, compounded,
24 assembled, processed, marketed, labeled, distributed, and sold the device into the stream
25 of commerce, the device was defective and presented a substantial danger to users of the

1 product when put to its intended and reasonably anticipated use, namely as an implanted
2 port/catheter system to administer the medications. Defendants failed to adequately warn
3 of the device's known or reasonably scientifically knowable dangerous propensities, and
4 further failed to adequately provide instructions on the safe and proper use of the device.

5 82. Defendants knew or should have known at the time they manufactured,
6 labeled, distributed and sold the Vortex that was implanted into Plaintiff that the Vortex
7 posed a significant and higher risk than other similar devices of device failure and
8 resulting serious injuries.

9 83. Defendants failed to timely and reasonably warn of material facts regarding
10 the safety and efficacy of the Vortex; no reasonable health care provider, including
11 Plaintiff's, or patient would have used the device in the manner directed, had those facts
12 been made known to the prescribing healthcare providers or the consumers of the device.

13 84. The warnings, labels, and instructions provided by the Defendants at all
14 times relevant to this action, are and were inaccurate, intentionally misleading, and
15 misinformed and misrepresented the risks and benefits and lack of safety and efficacy
16 associated with the device.

17 85. The health risks associated with the device as described herein are of such a
18 nature that ordinary consumers would not have readily recognized the potential harm.

19 86. The device, which was designed, manufactured, prepared, compounded,
20 assembled, processed, marketed, labeled, distributed, and sold into the stream of
21 commerce by Defendants, was defective at the time of release into the stream of
22 commerce due to inadequate warnings, labeling and/or instructions accompanying the
23 product.

1 87. When Plaintiff was implanted with the device, Defendants failed to provide
2 adequate warnings, instructions, or labels regarding the severity and extent of health risks
3 posed by the device, as discussed herein.

4 88. In performing the foregoing acts, omissions, and misrepresentations,
5 Defendants acted grossly negligent, fraudulently, and with malice so as to justify an
6 award of punitive and/or exemplary damages.

7 89. As a direct and proximate result of the aforementioned, Plaintiff was injured
8 due to the use of the Vortex, which caused Plaintiff various physical, mental, and
9 emotional injuries and damages. Accordingly, Plaintiff seeks compensatory damages.

10 **THIRD CAUSE OF ACTION**
11 **STRICT LIABILITY – DESIGN DEFECT**

12 90. Plaintiff incorporates by reference the preceding paragraphs of this
13 Complaint as if fully set forth herein.

14 91. The Vortex implanted in Plaintiff was not reasonably safe for its intended
15 use and was defective with respect to its design.

16 92. The Vortex was in a defective condition at the time that it left the possession
17 or control of Defendants.

18 93. The Vortex was unreasonably dangerous to the user or consumer.

19 94. The Vortex was expected to and did reach the consumer without substantial
20 change in its condition.

21 95. Defendants are strictly liable to the Plaintiff for designing, manufacturing,
22 marketing, labeling, packaging and selling a defective product.

23 96. As a direct and proximate result of the Vortex's aforementioned defects,
24 Plaintiff was injured due to the use of the Vortex, which caused Plaintiff various physical,
25

1 mental, and emotional injuries and damages. Accordingly, Plaintiff seeks compensatory
2 damages.

3 97. Defendants intentionally underreported the number and nature of adverse
4 events associated with dislodgement and migration of the devices to Plaintiff's health
5 care providers, as well as the FDA.

6 98. Neither Plaintiff nor Plaintiff's health care providers knew of the substantial
7 danger associated with the intended and foreseeable use of the device as described herein.

8 99. Plaintiff and Plaintiff's health care providers used the Vortex in a normal,
9 customary, intended, and foreseeable manner, namely as a surgically placed device used
10 to make it easier to deliver medications directly into the Plaintiff's bloodstream.
11 Moreover, Plaintiff's health care providers did not place or maintain the device
12 incorrectly such that it caused the device to "pinch off" or otherwise malfunction.

13 100. Upon information and belief, the defective and dangerous condition of the
14 device, including the one implanted into Plaintiff, existed at the time they were
15 manufactured, prepared, compounded, assembled, processed, marketed, labeled,
16 distributed, and sold by Defendants to distributors and/or healthcare professionals or
17 organizations. Upon information and belief, the device implanted in Plaintiff was in the
18 same condition as when it was manufactured, inspected, marketed, labeled, promoted,
19 distributed and sold by Defendants.

20 101. Defendants' lack of sufficient warning and/or instructions was the direct and
21 proximate cause of Plaintiff's serious physical injuries, and economic damages in an
22 amount to be determined at trial. In other words, had Defendants provided adequate
23 warnings, Plaintiff and his physicians would not have used the device.

1 102. In performing the foregoing acts, omissions, and misrepresentations,
2 Defendants acted grossly negligent, fraudulently, and with malice so as to justify an
3 award of punitive and/or exemplary damages.

4 103. As a direct and proximate result of the aforementioned, Plaintiff was injured
5 due to the use of the Vortex, which caused Plaintiff various physical, mental, and
6 emotional injuries and damages. Accordingly, Plaintiff seeks compensatory damages.

7 **FOURTH CAUSE OF ACTION**
8 **BREACH OF IMPLIED WARRANTY**

9 104. Plaintiff incorporates by reference the preceding paragraphs of this
10 Complaint as if fully set forth herein.

11 105. Defendants impliedly warranted that the Vortex was merchantable and fit
12 for the ordinary purposes for which it was intended.

13 106. When the Vortex was implanted in Plaintiff, it was being used for the
14 ordinary purposes for which it was intended.

15 107. Plaintiff, individually and/or by and through Plaintiff's physician, relied
16 upon Defendants' implied warranties of merchantability in consenting to have the Vortex
17 implanted in him.

18 108. Defendants breached these implied warranties of merchantability because
19 the Vortex implanted in Plaintiff was neither merchantable nor suited for its intended uses
20 as warranted.

21 109. Defendants' breaches of their implied warranties resulted in the implantation
22 of unreasonably dangerous and defective Vortex in Plaintiff's body, placing said
23 Plaintiff's health and safety in jeopardy.

24 110. The Vortex was sold to Plaintiff's health care providers for implantation in
25 patients, such as Plaintiff.

1 111. As a direct and proximate result of the aforementioned, Plaintiff was injured
2 due to the use of the Vortex, which caused Plaintiff various physical, mental, and
3 emotional injuries and damages. Accordingly, Plaintiff seeks compensatory damages.

4 **FIFTH CAUSE OF ACTION**
5 **BREACH OF EXPRESS WARRANTY**

6 112. Plaintiff incorporates by reference the preceding paragraphs of this
7 Complaint as if fully set forth herein.

8 113. Defendants, through their officers, directors, agents, representatives, and
9 written literature and packaging, and written and media advertisement, expressly
10 warranted that the Vortex was safe and fit for use by consumers, was of merchantable
11 quality, did not produce dangerous side effects, and was adequately tested and fit for its
12 intended use.

13 114. The Vortex does not conform to the Defendants' express representations
14 because it is not reasonably safe, has numerous serious side effects, and causes severe
15 and permanent injury.

16 115. At all relevant times, the Vortex did not perform as safely as an ordinary
17 consumer would expect, when used as intended or in a reasonably foreseeable manner.

18 116. Plaintiff, Plaintiff's physicians, and the medical community reasonably
19 relied upon the Defendants' express warranties for the Vortex.

20 117. At all relevant times, the Vortex was used on Plaintiff by Plaintiff's
21 physicians for the purpose and in the manner intended by Defendants.

22 118. Plaintiff and Plaintiff's physicians, by the use of reasonable care, could not
23 have discovered the breached warranty and realized its danger.

24 119. Upon information and belief, Plaintiff's healthcare providers sent notice to
25 Defendants of the adverse event that occurred to Plaintiff and thus, the nonconformity of

1 the Vortex, within a reasonable period of time following discovery of the breach of
2 warranty and before suit was filed.

3 120. As a direct and proximate result of the aforementioned, Plaintiff was injured
4 due to the use of the Vortex, which caused Plaintiff various physical, mental, and
5 emotional injuries and damages. Accordingly, Plaintiff seeks compensatory damages.

6 **SIXTH CAUSE OF ACTION**
7 **FRAUDULENT CONCEALMENT**

8 121. Plaintiff incorporates by reference the preceding paragraphs of this
9 Complaint as if fully set forth herein.

10 122. Defendants fraudulently concealed information with respect to the Vortex
11 in the following particulars:

- 12 a. Defendants represented through the labeling, advertising, marketing
13 materials, seminar presentations, publications, notice letters, and regulatory
14 submissions that the Vortex was safe and fraudulently withheld and
15 concealed information about the substantial risks of using the Vortex;
- 16 b. Defendants represented that the Vortex was safer than other alternative
17 systems and fraudulently concealed information which demonstrated that
18 the Vortex was not safer than alternatives available on the market;
- 19 c. Defendants concealed that it knew these devices were fracturing and
20 migrating from causes other than the manner in which the implanting
21 physician implanted the device; and
- 22 d. That frequency of these failures and the severity of injuries were
23 substantially worse than had been reported.

24 123. The Defendants had sole access to material facts concerning the dangers and
25 unreasonable risks of the Vortex.

1 the product entailed given the large number of adverse events Defendants knew or should
2 have been aware of but did not adequately disclose to Plaintiff.

3 137. Defendants' practices were likely to mislead consumers who acted
4 reasonably to their detriment in purchasing the product based on Defendants'
5 representations that it was reasonably safe for use when it in fact was not and had a higher
6 risk of infection and thrombosis due to its defective design.

7 138. Defendants intended for Plaintiff, Plaintiff's physicians, and other
8 consumers to rely on their deceptive practices and representations in order to continue
9 selling and manufacturing the Vortex.

10 139. As a result of Defendants' conduct, Plaintiff suffered actual damages in that
11 the product Plaintiff purchased was misrepresented and worth far less than the product
12 Plaintiff thought had been purchased, had Defendants' representations been true.

13 140. As a direct and proximate result of the aforementioned, Plaintiff was injured
14 due to the use of the Vortex, which caused Plaintiff various physical, mental, and
15 emotional injuries and damages. Accordingly, Plaintiff seeks compensatory damages.

16 **PUNITIVE DAMAGES**

17 141. Plaintiff is entitled to an award of punitive and exemplary damages based
18 upon Defendants' intentional, willful, knowing, fraudulent, malicious acts, omissions,
19 and conduct, and their complete and total reckless disregard for the public safety and
20 welfare. Defendants intentionally and fraudulently misrepresented facts and information
21 to both the healthcare community and the general public, including Plaintiff and
22 Plaintiff's health care providers, by making intentionally false and fraudulent
23 misrepresentations about the safety and efficacy of the Vortex. Defendants intentionally
24 concealed the true facts and information regarding the serious risks of harm associated
25 with the implantation of said product, and intentionally downplayed the type, nature, and

1 extent of the adverse side effects of being implanted with the device, despite Defendants’
2 knowledge and awareness of the serious and permanent side effects and risks associated
3 with use of same. Defendants further intentionally sought to mislead health care providers
4 and patients, including Plaintiff and Plaintiff’s health care providers, regarding the cause
5 of infection, thrombosis and failures of the Vortex.

6 142. Defendants had knowledge of and were in possession of evidence
7 demonstrating that the Vortex caused serious physical side effects. Defendants continued
8 to market said product by providing false and misleading information with regard to the
9 product’s safety and efficacy to the regulatory agencies, the medical community, and
10 consumers of the Vortex, notwithstanding Defendants’ knowledge of the true serious side
11 effects of the Vortex, Defendants failed to provide accurate information and warnings to
12 the healthcare community that would have dissuaded physicians from surgically
13 implanting the Vortex and consumers from agreeing to being implanted with the Vortex,
14 thus depriving physicians and consumers from weighing the true risks against the benefits
15 of prescribing and implanting the Vortex.

16 143. As a direct, proximate, and legal result of Defendants’ acts and omissions
17 as described herein, and Plaintiff’s implantation with Defendants’ defective product,
18 Plaintiff suffered the injuries and damages described in this complaint.

19 **WHEREFORE**, Plaintiff demands judgment against Defendants for
20 compensatory, special, and punitive damages, together with interest, costs of suit,
21 attorneys’ fees, and all such other relief as the Court deems proper.

22 **PRAYER**

23 **WHEREFORE**, Plaintiff prays for judgment against each of the Defendants as
24 follows:

- 1 a. Judgement be entered against all Defendants on all causes of action of this
- 2 Complaint;
- 3 b. Plaintiff be awarded her full, fair, and complete recovery for all claims and
- 4 causes of action relevant to this action;
- 5 c. Plaintiff be awarded general damages according to proof at the time of trial;
- 6 d. Plaintiff be awarded damages, including past medical expenses according to
- 7 proof at the time of trial;
- 8 e. Plaintiff be awarded punitive damages according to proof at the time of trial;
- 9 f. Plaintiff be awarded actual damages, attorneys' fees and costs in connection
- 10 with Plaintiff's claims under Washington's Consumer Protection Act, RCW
- 11 §19.86;
- 12 g. Plaintiff be awarded punitive damages according to awarding pre-judgment
- 13 and post-judgment interest to the Plaintiff;
- 14 h. Plaintiff be awarded the costs and the expenses of this litigation to the
- 15 Plaintiff; and
- 16 i. For such other and further relief as the court may deem just and proper.
- 17

18 Dated: April 2, 2026

By: /s/ Timothy R. West

19 Timothy R. West, CA Bar #342526
20 **DV INJURY LAW WEST, PC /**
21 **UTB LAW GROUP**
22 404 Camino Del Rio S, Suite 606
23 San Diego, CA 92108
24 T: (619) 202-0004
25 F: (619) 825-2661
26 timw@dvinjurylaw.com

Attorneys for Plaintiff